Akèy › Kansè Poumon ki pa ti selil › Iowa › Des Moines
Etid klinik pou Kansè Poumon ki pa ti selil nan Des Moines, IA
11 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Des Moines (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Iowa Methodist Medical Center, Des Moines
- UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines
- Broadlawns Medical Center, Des Moines
- ak 5 plis
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Iowa Methodist Medical Center, Des Moines
- UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines
- Broadlawns Medical Center, Des Moines
- ak 5 plis
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- University of Iowa Health Care, Mission Cancer + Blood, Waukee · 14 mi lwen
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Des Moines
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Site, Waukee · 14 mi lwen
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Mission Cancer + Blood - IMMC, Des Moines
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Ap rekriteFaz 3
- Iowa Methodist Medical Center, Des Moines
- UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines
- Mercy Medical Center - Des Moines, Des Moines
- ak 4 plis
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Iowa Methodist Medical Center, Des Moines
- UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines
- Mercy Medical Center - Des Moines, Des Moines
- ak 4 plis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Iowa Methodist Medical Center, Des Moines
- UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines
- UI Health Care Mission Cancer and Blood - Laurel Clinic, Des Moines
- ak 3 plis
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Ap rekriteFaz 2
- Mission Cancer + Blood - Mission Cancer Foundation, Des Moines
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Iowa Methodist Medical Center, Des Moines
- UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines
- Broadlawns Medical Center, Des Moines
- ak 6 plis
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Des Moines
- Kansè poumon10 etid
- Kansè nan tete8 etid
- Kansè kolorektal8 etid
- Lukemi lenfositè kwonik8 etid
- Kansè vejik6 etid
- Sipwa6 etid
- Myelom Miltip5 etid
- Obèsite5 etid
- Leksemi mieloïd egi5 etid
- Dyabèt Tip 25 etid
- Maladi kadyovaskilè5 etid
- Limfom Difize Gwo Selil B5 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.